differ
strategi
work
engin
origin
baculoviru
express
vector
bev
system
produc
costeffect
clinic
biolog
commerci
scale
date
thousand
highli
variabl
molecul
form
heterolog
protein
viruslik
particl
surfac
display
proteinsantigen
carrier
heterolog
viral
vector
gene
deliveri
vehicl
produc
use
system
product
use
vaccin
product
tissu
engin
stem
cell
transduct
viral
vector
product
gene
therapi
cancer
treatment
develop
biosensor
recombin
protein
express
posttransl
modifi
use
system
also
suitabl
function
crystallograph
studi
microarray
drug
discoverybas
applic
till
four
bevbas
commerci
product
cervarix
proveng
glybera
flublok
approv
human
myriad
other
differ
stage
preclin
clinic
trial
five
product
porcili
pesti
bayovac
csf
circumv
pcv
ingelvac
circoflex
porcili
pcv
got
approv
veterinari
use
mani
pipelin
present
chapter
emphas
approv
baculovirusbas
product
produc
insect
cell
larva
import
clinic
perspect
develop
prevent
diagnost
therapeut
agent
potenti
recombin
adenoassoci
viru
raav
gene
deliveri
vector
describ
system
due
rel
extend
gene
express
lack
pathogen
abil
transduc
baculoviru
famili
baculovirida
deriv
name
latin
word
baculum
mean
stick
rodshap
nm
larg
envelop
virus
circular
supercoil
doublestrand
dna
genom
approxim
kb
size
baculovirus
infect
natur
host
ie
butterfli
moth
lepidoptera
also
known
infect
sawfli
hymenoptera
mosquito
diptera
king
et
al
link
diseas
organ
outsid
phylum
arthropoda
kost
condreay
baculovirus
well
known
role
biopesticid
effici
tool
heterogen
protein
product
insect
cell
summer
morpholog
envelop
virus
classifi
two
phenotyp
occlusionderiv
virus
odv
embed
paracrystallin
matrix
form
polyhedr
occlus
bodi
ob
respons
horizont
transmiss
insect
bud
virus
buv
present
haemolymph
spread
infect
cell
cell
luckow
summer
occlus
bodi
morpholog
initi
use
defin
two
major
group
baculovirus
nucleopolyhedrovirus
npv
granulovirus
gv
npv
obtain
envelop
host
nuclear
membran
occlud
within
main
occlus
protein
polyhedrin
form
larg
polyhedr
inclus
bodi
gv
obtain
envelop
cell
membran
make
ovalshap
singl
virion
structur
call
granul
capsul
diamet
rang
king
et
al
npv
distinguish
singl
nucleopolyhedroviru
multipl
nucleopolyhedroviru
base
number
nucleocapsid
polyhedr
inclus
bodi
oreilli
et
al
ob
allow
virion
remain
infecti
long
period
due
highli
resist
stabl
structur
baculovirusinfect
insect
cell
express
system
use
routin
product
recombin
protein
includ
sever
protein
therapeut
natur
last
three
decad
establish
system
begin
product
human
beta
interferon
protein
normal
produc
cultur
human
cell
produc
recombin
autographa
californica
multipl
nucleopolyhedroviru
acmnv
exploit
polyhedrin
promot
smith
et
al
system
protein
code
sequenc
human
interferon
gene
link
acnpv
polyhedrin
gene
promot
interferon
gene
insert
differ
posit
rel
acnpv
polyhedrin
transcript
translat
signal
interferonpolyhedrin
hybrid
plasmid
transfer
infecti
acnpv
express
vector
recombin
within
frugiperda
insect
cell
biolog
activ
glycosyl
interferon
produc
secret
form
time
anoth
group
success
express
escherichia
coli
gene
insect
cell
use
system
kb
plasmid
construct
made
gene
kb
fusion
ntermin
region
polyhedrin
gene
kb
acnpv
cotransfect
fuse
plasmid
construct
wildtyp
acnpv
genom
dna
kb
perform
order
insert
foreign
gene
polyhedrin
gene
acnpv
genom
process
homolog
recombin
final
recombin
virus
select
blue
plaqu
presenc
indic
xgal
medium
discoveri
mark
begin
baculoviru
express
system
facilit
engin
improv
baculoviru
vector
modif
sugar
moieti
glycoprotein
express
insect
cell
scale
cell
cultur
process
baculoviru
express
vector
bev
platform
tailor
take
advantag
baculovirus
natur
tendenc
infect
insect
cell
almost
differ
type
baculovirus
specif
infect
invertebr
laboratori
research
manufactur
purpos
commonli
studi
baculoviru
autographa
californica
multipl
nucleopolyhedroviru
acmnpv
often
consid
prototyp
baculovirus
doublestrand
circular
dna
genom
kb
insid
rodshap
nucleocapsid
size
nm
fauquet
et
al
larg
size
genom
give
suffici
abil
accommod
larg
foreign
dna
multipl
gene
togeth
typic
recombin
bev
construct
cotransfect
mixtur
transfer
plasmid
modifi
noninfecti
linear
acmnpv
lack
parent
polyhedrin
gene
portion
transfer
plasmid
contain
gene
interest
goi
flank
upstream
strong
polyhedrin
promot
downstream
essenti
portion
acmnpv
highlevel
protein
express
insect
cell
transfer
plasmid
modifi
linear
acmnpv
dna
undergo
homolog
recombin
gener
de
novo
recombin
baculovirus
plate
baculovirus
singl
pure
plaqu
recombin
baculoviru
select
subsequ
plaqu
passag
multipl
round
insect
cell
infect
gener
hightitr
stock
creat
work
viru
bank
wvb
util
downstream
process
system
enhanc
manufactur
commerci
purpos
multipl
way
technolog
bacmid
technolog
bac
bac
life
technolog
employ
gener
recombin
acmnpv
genom
bacteri
host
system
e
coli
flashbacktm
oxford
express
technolog
ltd
bacmagictm
merck
baculoonetm
paa
technolog
use
avoid
bacteri
sequenc
final
vector
rapid
product
multipl
recombin
virus
onestep
procedur
multibac
system
use
synthesi
multisubunit
protein
complex
omnibac
multigen
transfer
vector
univers
gener
recombin
baculovirus
sleep
beauti
piggybac
transposon
system
exploit
highli
effici
seamless
excis
transposon
genom
dna
potenti
target
integr
event
desir
dna
sequenc
product
acmnpv
vector
recombin
protein
spodoptera
frugiperda
subclon
high
five
cell
line
use
insect
cell
exhibit
sever
properti
like
rapid
growth
stress
resist
robust
express
recombin
protein
make
suitabl
product
clinic
biolog
commerci
product
initi
insectderiv
baculoviru
express
vector
bev
recogn
safe
system
routin
product
recombin
protein
insect
mammalian
cell
last
three
decad
emerg
effect
tool
research
well
variou
applic
field
biotechnolog
shown
tremend
potenti
prevent
diagnost
therapeut
agent
myriad
diseas
form
vaccin
tissu
engin
stem
cell
transduct
viral
vector
product
gene
therapi
airenn
et
al
extens
use
function
studi
crystallographi
biosensor
protein
microarray
drug
discoveri
applic
base
differ
baculovirusderiv
product
heterolog
protein
proteinantigen
display
baculoviru
particl
surfac
heterolog
viral
vector
gene
deliveri
vehicl
mammalian
cell
van
oer
et
al
chapter
present
applic
product
clinic
point
view
three
main
categori
viz
prevent
diagnost
therapeut
agent
approv
biomolecul
produc
use
baculoviru
express
system
insect
cell
discuss
thousand
product
develop
bev
seem
ineffectu
includ
entir
list
ambit
present
chapter
howev
among
mention
understand
scope
power
express
system
near
futur
bev
exhibit
mani
characterist
make
suitabl
product
heterolog
protein
insect
cell
easili
handl
laboratori
due
harmless
natur
nontarget
organ
virus
environment
safe
due
instabl
outsid
laboratori
use
produc
high
level
protein
insect
cell
larva
eukaryot
environ
provid
appropri
posttransl
modif
bev
host
insect
cell
mostli
free
human
pathogen
requir
control
oxygen
environ
growth
insect
cell
grown
serumfre
medium
heterolog
protein
product
enhanc
level
pilot
plant
larger
bioreactor
therefor
protein
obtain
bev
use
vaccin
either
form
heterolog
subunit
protein
viruslik
particl
vlp
form
subunit
protein
viru
subunit
vaccin
rel
safe
devoid
viru
genet
materi
exhibit
poor
immunogen
might
due
incorrect
fold
target
protein
structur
protein
virus
capsid
envelop
protein
assembl
particul
structur
similar
natur
occur
viru
subvir
particl
therefor
viruslik
particl
vlp
noninfecti
nonrepl
due
absenc
viral
genet
materi
produc
heterolog
system
yamaji
vlp
highli
effect
elicit
humor
cellular
immun
respons
dens
repeat
display
viral
antigen
right
conform
roy
noad
vlp
compar
exhibit
wide
spectrum
clinic
applic
prevent
diseas
vaccin
diagnost
antigen
detect
antibodi
therapeut
form
therapeut
vaccin
deliveri
agent
use
heterolog
protein
vlp
prevent
agent
form
vaccin
differ
diseas
describ
tabl
decad
back
two
veterinari
product
manufactur
use
bev
prevent
classic
swine
fever
pig
five
new
vaccin
approv
two
human
mani
product
develop
phase
approv
vaccin
well
develop
vaccin
preclin
stage
highlight
subunit
marker
vaccin
classic
swine
fever
classic
swine
fever
viru
csfv
infect
invari
develop
antibodi
viru
envelop
protein
e
rn
glycoprotein
nonstructur
protein
swine
paton
et
al
howev
inject
glycoprotein
pig
report
suffici
provid
protect
csfv
van
rijn
et
al
therefor
subunit
vaccin
produc
basi
conserv
glycoprotein
baculoviru
vector
insect
cell
moormann
et
al
glycoprotein
express
envelop
protein
ctermin
transmembran
domain
remov
secret
medium
residu
baculoviru
inactiv
vaccin
manufactur
commerci
porcili
pesti
msd
anim
health
vaccin
also
commerci
bayovac
csf
advasurea
bayer
agpfiz
anim
health
later
discontinu
b
viruslik
particl
vlp
base
vaccin
porcin
circoviru
type
porcin
circoviru
type
vaccin
develop
base
vlp
primari
caus
agent
postwean
multisystem
wast
syndrom
pmw
swine
two
major
open
read
frame
identifi
encod
major
structur
protein
typespecif
epitop
found
highli
immunogen
therefor
encod
capsid
protein
use
develop
vaccin
baculoviru
insect
cell
liu
et
al
msd
anim
health
got
product
licens
two
name
differ
geograph
area
prevent
diagnost
therapeut
applic
c
vlpbase
vaccin
porcin
parvoviru
ppv
ppv
nonenvelop
dna
viru
caus
major
reproduct
failur
swine
viral
capsid
made
molecul
major
structur
protein
target
vaccin
develop
gene
express
control
late
promot
baculoviru
lacz
gene
control
drosophila
hsp
promot
recombin
baculoviru
use
infect
insect
cell
line
express
lead
selfassembl
empti
ppv
vlp
serumfre
medium
safeti
point
view
maranga
et
al
earlier
also
produc
cell
presenc
serum
protein
howev
commerci
larg
scale
still
need
development
effort
monoval
bival
vlp
vaccin
develop
two
serotyp
btv
exhibit
protect
virul
btv
live
strain
compar
earlier
vlp
express
capsid
protein
develop
cotransfect
dual
transfer
vector
dna
wildtyp
acnpv
dna
insect
cell
french
et
al
strong
development
effort
research
need
commerci
robust
effect
btv
vaccin
mani
vlp
veterinari
vaccin
baculoviru
express
system
insect
cell
develop
avian
influenza
ai
vlp
consist
subunit
haemagglutinin
ha
neuraminidas
na
matrix
protein
ai
viru
duck
prel
et
al
chimer
infecti
bursal
diseas
viru
ibdv
vlp
consist
structur
protein
vari
degre
one
capsid
protein
tag
histidin
ibdv
chicken
hu
bentley
rabbit
haemorrhag
diseas
viru
rhdv
vlp
made
capsid
protein
rabbit
laurent
et
al
simian
immunodefici
viru
siv
vlp
consist
precursor
protein
gag
vaccin
test
nonhuman
primat
yamshchikov
et
al
subunit
vaccin
influenza
influenza
gener
call
flu
caus
rna
influenza
virus
design
type
c
type
b
influenza
virus
possess
haemagglutinin
ha
neuraminidas
na
glycoprotein
spike
envelop
act
key
antigen
host
immun
respons
therefor
target
vaccin
develop
ha
na
exhibit
antigen
drift
due
continu
mutat
genet
materi
vaccin
base
glycoprotein
requir
updat
annual
howev
type
c
influenza
viru
involv
annual
influenza
viru
vaccin
caus
mild
respiratori
diseas
human
advent
success
case
approv
vlpbase
vaccin
research
inde
redirect
effort
develop
product
therefor
number
vaccin
produc
mani
viral
diseas
human
howev
mani
either
preclin
clinic
trial
stage
promin
vlp
made
multimer
protein
express
insect
cell
includ
ebola
glycoprotein
sun
et
al
enteroviru
chung
et
al
human
parvoviru
et
al
norwalk
viru
nv
capsid
protein
jiang
et
al
ball
et
al
atmar
et
al
frey
polyomaviru
montross
et
al
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
sp
ep
mp
en
mortola
roy
simian
viru
kanesashi
et
al
vlp
rotaviru
prepar
use
two
three
capsid
protein
express
high
five
insect
cell
also
express
sf
larva
two
capsid
protein
et
al
combin
capsid
protein
differ
strain
influenza
use
high
five
insect
cell
ha
ha
produc
higher
amount
influenza
avlp
influenza
avlp
form
coexpress
produc
high
five
cell
strainspecif
influenza
ha
capsid
protein
use
prepar
influenza
influenza
insect
cell
krammer
et
al
et
al
respiratori
syncyti
viru
rsv
vaccin
produc
use
rsvf
protein
mazur
et
al
neuzil
hiv
vlp
produc
target
gag
protein
rodent
rhesu
macaqu
preclin
trial
pillay
et
al
wagner
et
al
supposedli
heterolog
subunit
protein
vlpbase
subunit
vaccin
use
vaccin
well
antigen
detect
antibodi
given
condit
satisfi
variou
diagnost
paramet
like
sensit
specif
predict
valu
likelihood
ratio
paramet
well
evalu
found
accept
diagnost
purpos
numer
bevderiv
product
howev
commerci
vaccinesprotein
demand
standard
evalu
summar
human
well
veterinari
usag
diagnost
molecul
produc
bev
system
insect
cell
tabl
eshaghi
et
al
use
diagnost
reagent
human
need
explor
protein
gene
swine
vesicular
diseas
viru
svdv
deriv
vlp
antigen
detect
antibodi
svdv
pig
elisa
also
develop
ko
et
al
c
hors
recombin
baculoviru
express
equin
infecti
anaemia
viru
eiav
core
protein
gag
antigen
found
possess
high
specif
sensit
elisa
agar
gel
immunodiffus
agid
detect
antibodi
infect
hors
sera
kong
et
al
haemagglutinin
ha
sugiura
et
al
effici
test
subunit
ha
sguazza
et
al
cattl
baculovirusderiv
antigen
captur
competit
elisa
ag
cap
celisa
diagnosi
bluetongu
epizoot
haemorrhag
diseas
viru
infect
cattl
exhibit
advantag
term
easi
product
standard
less
requir
downstream
process
noninfecti
natur
compar
commerci
avail
celisa
mecham
wilson
block
elisa
develop
bev
detect
antibodi
footandmouth
diseas
cattl
pig
goat
viru
type
specif
ko
et
al
bovin
respiratori
syncyti
viru
brsv
infect
caus
lower
respiratori
tract
diseas
calv
month
old
detect
immunofluoresc
analysi
recombin
fprotein
antigen
pastey
samal
e
bird
variant
elisa
known
eelisa
use
eukaryot
express
e
protein
antigen
detect
tembusu
viru
tmuv
duck
develop
specif
sensit
yin
et
al
recombin
avian
paramyxoviru
type
haemagglutinin
found
use
altern
antigen
haemagglutin
inhibit
hi
test
detect
infect
avian
choi
et
al
whole
sendai
viru
virion
vlp
use
antigen
detect
antibodi
viru
diagnost
purpos
major
capsid
protein
goos
haemorrhag
polyomavirusvlp
detect
ghpvspecif
antibodi
sera
flock
haemorrhag
nephriti
enter
gees
hneg
diseas
zielonka
et
al
recombin
protein
use
antigen
express
baculoviru
express
system
insect
cell
unless
otherwis
state
mention
lassa
viru
infect
caus
lassa
fever
mainli
endem
west
africa
recombin
nucleocapsid
protein
act
antigen
detect
antibodi
lassa
virusinfect
patient
sera
elisa
barber
et
al
saijo
et
al
rubella
viru
rv
normal
caus
selflimit
diseas
infect
first
trimest
pregnanc
may
caus
foetal
damag
therefor
serolog
diagnost
test
develop
express
polyprotein
precursor
rubella
viru
antigen
enzym
immunoassay
eia
immunoblot
analysi
patient
sera
et
al
trypanosoma
cruzi
caus
chaga
diseas
latin
america
flagellar
repetit
antigen
fra
part
cruzibas
improv
diagnost
assay
develop
chaga
diseas
do
santo
et
al
fulllength
human
glutam
acid
decarboxylas
histidin
tag
produc
natur
conform
develop
immunoassay
diagnosi
insulindepend
diabet
mellitu
mauch
et
al
hantaviru
caus
haemorrhag
fever
renal
syndrom
hfr
nucleocapsid
protein
strain
use
antigen
indirect
immunofluoresc
antibodi
ifa
diagnost
test
detect
three
serotyp
hantan
puumala
hantaviru
yoshimatsu
et
al
purifi
human
papillomaviru
hpv
protein
use
develop
elisa
detect
igg
iga
respons
cervic
neoplasia
patient
rochazavaleta
et
al
human
caliciviru
hucv
strain
one
three
clade
sapporolik
hucv
caus
acut
gastroenter
children
viral
capsid
gene
capsid
use
antigen
immunoprecipit
eia
jiang
et
al
herp
simplex
viru
hsv
infect
caus
two
virus
diagnost
test
distinguish
two
strain
develop
util
typespecif
typecommon
hsv
antigen
singlestep
assay
format
perform
accur
diagnosi
burk
wald
ashleymorrow
liu
et
al
eight
differ
strain
human
calicivirus
hucv
capsid
protein
use
develop
antigenantibodi
detect
assay
eia
highli
specif
jiang
et
al
caus
agent
tickborn
enceph
tbe
cterminu
truncat
form
protein
e
etr
tbe
complex
viru
tag
histidin
use
develop
sensit
specif
elisa
well
immunoblot
assay
detect
tbe
virusspecif
antibodi
infect
individu
marx
et
al
fel
dl
major
allergen
cat
consist
two
polypeptid
chain
chain
chain
usual
link
disulphid
bond
recombin
fel
dl
rfel
dl
protein
construct
two
chain
link
togeth
glycineserin
linker
use
potent
antigen
bacterialderiv
protein
detect
ige
igg
antibodi
radioimmunoassay
ria
elisa
guyr
et
al
coeliac
diseas
cd
character
presenc
autoantigen
transglutaminas
tg
recombin
human
tissu
tg
huttg
express
baculoviru
system
use
antigen
elisa
show
sensit
specif
osman
et
al
envelop
glycoprotein
gb
gd
gc
ge
gg
thought
primari
target
igg
antibodi
respons
patient
herp
b
viru
hbv
infect
therefor
elisa
test
develop
use
cocktail
recombin
glycoprotein
along
capsid
protein
high
sensit
specif
perelygina
et
al
similarli
recombin
protein
singl
multipl
subunit
diagnosi
differ
type
viral
infect
human
develop
baculoviru
express
system
insect
cell
bev
express
product
like
growth
factor
cytokin
chemokin
enzym
hormon
monoclon
antibodi
use
human
therapeut
purpos
recent
bev
also
exploit
effect
tool
gene
therapi
simplic
applic
product
divid
two
major
group
biolog
drug
therapi
gene
therapi
thousand
biomolecul
develop
till
system
among
discuss
tabl
bev
util
eukaryot
express
vector
insect
cell
product
therapeut
immunotherapeut
protein
monoclon
antibodi
cytokin
chemokin
growth
factor
etc
requir
posttransl
modif
importantli
glycosyl
baculoviru
express
system
accept
one
effici
power
technolog
product
biolog
recombin
term
achiev
quantiti
puriti
eas
eukaryot
process
luckow
summer
therapeut
recombin
protein
product
consid
essenti
section
emerg
biotechnolog
industri
system
potenti
develop
high
commerci
valu
industri
immunotherapi
year
numer
tumour
immunotherapi
achiev
earlystag
success
fail
clinic
trial
phaseiii
goldman
defrancesco
baculovirusderiv
dendreon
proveng
seattl
sipuleucelt
prostat
cancer
among
first
therapeut
cancer
vaccin
complet
phaseiii
trail
success
receiv
fda
approv
proveng
sipuleucelt
autolog
activ
cellular
immunotherapi
shown
evid
reduc
risk
death
among
men
metastat
castrationresist
prostat
cancer
kantoff
et
al
consist
autolog
peripheralblood
mononuclear
cell
pbmc
includ
antigenpres
cell
apc
activ
ex
vivo
recombin
fusion
protein
fusion
protein
contain
prostat
antigen
prostat
acid
phosphatas
fuse
immunecel
activ
call
granulocytemacrophag
colonystimul
factor
produc
bev
insect
cell
monoclon
antibodi
prepar
colorect
cancer
cell
use
pfastbac
vector
park
et
al
bev
express
protein
util
product
monoclon
antibodi
bcell
lymphoma
integr
membran
oncoprotein
regul
program
cell
death
apoptosi
haematolymphoid
cell
reed
et
al
singledomain
antibodi
sdab
prepar
rotaviru
infect
also
known
nanobodi
vhh
characterist
high
stabil
solubl
high
affin
antigen
antibodi
first
produc
insect
larva
trichoplusia
ni
serv
live
biofactori
product
biomolecul
et
al
antibreast
cancer
monoclon
antibodi
mab
without
fusion
kdel
lysaspgluleu
endoplasm
reticulum
retent
signal
prepar
heavi
chain
hc
light
chain
lc
gene
mab
clone
pfastbac
dual
vector
control
polyhedrin
p
ph
p
promot
respect
insect
cell
lee
et
al
antibodi
respons
enhanc
two
recombin
subunit
vaccin
tag
vaccin
adjuv
recombin
singlechain
antibodi
recogn
mhc
class
ii
dr
produc
trichoplusia
ni
insect
cell
gil
et
al
human
interleukin
prepar
insect
larva
ni
place
gene
promot
bev
pham
et
al
human
granulocytemacrophag
colonystimul
factor
hgmcsf
prepar
bombyx
mori
silkworm
nuclear
polyhedrosi
viru
bmnpv
shi
et
al
cytokin
chemokin
produc
use
express
system
similar
manner
recent
intraves
instil
transgen
devoid
baculoviru
found
elicit
local
immun
stimul
upregul
set
cytokin
orthotop
bladder
tumour
mice
ang
et
al
howev
applic
strategi
nonmuscl
invas
bladder
cancer
nmibc
human
await
b
enzym
hormon
therapi
enzym
human
adenosin
deaminas
key
purin
salvag
enzym
requir
immun
compet
produc
trichoplusia
ni
spodoptera
frugiperda
insect
cell
well
larva
enzym
possess
specif
activ
unitsmg
crude
homogen
time
higher
two
abund
natur
sourc
thymu
leukem
cell
biolog
activ
inexpens
rapid
huge
product
enzym
baculoviru
system
open
avenu
biolog
activ
molecul
human
parathyroid
hormon
hpth
produc
bombyx
mori
cell
larva
host
system
report
suitabl
effici
synthesi
secret
correctli
process
hpth
mathavan
et
al
similarli
recombin
full
length
human
growth
hormon
hgh
produc
bombyx
mori
nuclear
polyhedrosi
viru
vbmhgh
sumathi
et
al
c
growth
factor
therapi
growth
factor
natur
signal
molecul
requir
myriad
biolog
process
requir
consist
costeffect
clinic
effici
technolog
indispens
wound
heal
one
complex
biolog
process
requir
collabor
effort
differ
tissu
cell
molecul
repair
process
wound
injuri
initi
releas
variou
growth
factor
gf
gf
act
function
messeng
molecul
cell
control
cellular
process
regulatori
network
sometim
requir
recombin
protein
therapi
current
wound
heal
focuss
gf
andor
human
skin
substitut
requir
decreas
heal
time
modifi
inflamm
acceler
prolif
phase
benefici
effect
gf
attract
differ
kind
cell
site
wound
heal
demonstr
mani
studi
wider
clinic
commerci
applic
gf
depend
scalabl
costeffici
product
bev
success
unblock
bottleneck
inevit
three
fulli
function
human
gf
human
epiderm
growth
factor
human
fibroblast
growth
factor
human
keratinocyt
growth
factor
produc
bev
trichoplusia
ni
insect
larva
dudognon
et
al
express
found
enhanc
express
tag
human
antibodi
igg
fragment
crystallis
region
fc
human
prepro
beta
nerv
growth
factor
suggest
therapeut
agent
treatment
alzheim
diseas
produc
insect
cell
recombin
viru
matur
human
beta
nerv
growth
factor
rhngf
found
biolog
activ
cholinerg
cell
surviv
barnett
et
al
similarli
differ
strategi
work
bev
insect
cell
larva
biolog
activ
costeffect
therapeut
commerci
scale
product
numer
highli
variabl
molecul
today
gene
therapi
potenti
reach
point
wherebi
exploit
treat
mani
diseas
earlier
thought
untreat
requisit
modal
gene
drug
safeti
gener
immun
respons
durat
express
gene
deliveri
capac
success
realiz
baculovirusbas
vector
baculovirus
found
deliv
gene
wide
rang
vertebr
cell
speci
howev
exact
mechan
entri
baculoviru
host
cell
still
fulli
understood
recent
phagocyticlik
mechan
entri
mammalian
cell
found
convinc
pinocytosi
long
et
al
baculoviru
progeni
product
occur
two
form
bud
viru
buv
occlusionderiv
viru
differ
envelop
buv
deriv
envelop
cell
membran
spread
infect
within
host
wherea
occlusionderiv
viru
envelop
deriv
nuclear
membran
spread
infect
host
buv
wide
use
form
biotechnolog
enter
insect
host
endocytosi
mechan
although
tenet
exact
endocyt
mechan
still
need
build
acmnpv
prototyp
baculovirus
wide
use
differ
applic
includ
gene
therapi
abl
transduc
divid
nondivid
mammalian
cell
activ
transgen
target
cell
carri
control
specifi
promot
indic
nucleocapsid
baculoviru
transport
genom
across
intact
host
cell
nuclear
membran
nuclear
pore
complex
howev
detail
molecular
mechan
baculoviru
transduct
mammalian
cell
demand
investig
effici
gene
deliveri
bev
gene
deliveri
capabl
exploit
understand
mechan
vertebr
cell
transduct
preclin
studi
vaccin
cartilag
bone
tissu
engin
cancer
gene
therapi
assay
develop
drug
screen
gener
gene
therapi
vector
airenn
et
al
would
like
emphas
use
recombin
adenoassoci
vector
raav
gene
therapi
tool
highli
import
bioprocess
therapeut
perspect
therapi
recombin
aav
carri
therapeut
dna
turn
attract
gene
deliveri
vector
suitabl
vivo
gene
therapi
potenti
rel
longterm
gene
express
lack
pathogen
abil
transduc
wide
varieti
divid
nondivid
cell
nine
differ
serotyp
raav
use
gene
therapi
wherebi
serotyp
exhibit
differ
propens
tissuespecif
infect
infect
kinet
zincarelli
et
al
major
limit
low
product
quantiti
address
recent
optim
bev
platform
adjust
differ
paramet
multipl
infect
cell
densiti
ferment
mode
produc
vector
genom
per
litr
mena
et
al
strategi
raav
product
requir
product
three
aav
capsid
protein
capsid
protein
assembl
within
bevtransduc
insect
cell
produc
icosahedr
vlp
aucoin
et
al
effici
raav
requir
coinfect
insect
cell
three
differ
kind
baculovir
vector
first
one
bacrep
express
major
aav
replic
enzym
rep
rep
essenti
aav
genom
replic
packag
respect
second
baccap
express
aav
virion
capsid
protein
third
bacgoi
express
gene
interest
flank
aav
invert
termin
repeat
element
requir
rescu
replic
packag
heterolog
gene
coinfect
three
vector
insect
cell
produc
effici
replic
encapsul
singlestrand
aav
vector
genom
weyer
posse
enhanc
aav
term
stabil
robust
scalabl
hightitr
product
involv
rep
cap
protein
express
singl
baculoviru
bacrep
cap
ie
express
rep
rep
transcript
singl
mrna
genet
modif
origin
bacrep
baccap
construct
virag
et
al
develop
robust
gene
deliveri
vehicl
base
fact
aav
genom
effici
replic
insect
cell
line
repdepend
fashion
diseas
target
gene
therapi
use
raav
discuss
gene
therapi
lipoprotein
lipas
defici
lpld
rare
autosom
recess
genet
metabol
disord
inactiv
famili
lipoprotein
lipas
enzym
occur
due
mutat
gene
lpl
function
lipas
requir
plasma
triglycerid
hydrolysi
normal
condit
inactiv
enzym
result
hypertriglyceridemia
character
frequent
abdomin
pain
fatti
deposit
skin
retina
sever
case
lead
fatal
pancreat
diabet
onset
cardiovascular
diseas
earlier
therapi
target
lower
plasma
triglycerid
prove
much
effect
alipogen
tiparvovec
also
known
earli
phase
clinic
trial
first
adenoassoci
viru
aav
mediat
gene
therapi
manufactur
uniqur
got
market
author
govern
approv
europ
serotyp
vector
express
natur
occur
variant
lpl
transgen
lpl
link
improv
lipid
profil
commerci
name
glybera
gaudet
et
al
inject
intramuscular
rout
patient
result
natur
gain
function
lpl
gene
variant
muscl
tissu
glybera
use
significantli
lower
plasma
triglycerid
increas
lipoprotein
lipas
enzym
activ
major
concern
use
vectorbas
gene
therapi
prevent
humor
cellmedi
immun
respons
elicit
viral
capsid
protein
may
impact
efficaci
safeti
drug
intramuscular
inject
glybera
prove
clinic
safe
effici
drug
elicit
addit
system
local
immun
respons
harm
human
approach
found
relev
promis
treatment
thousand
singl
gene
disord
similar
strategi
investig
divers
rang
therapeut
area
mani
product
treatment
human
diseas
differ
stage
clinic
develop
aav
gene
therapi
drug
differ
clinic
develop
phase
discuss
b
haemophilia
blood
clot
disord
caus
mutat
clot
factor
ix
gene
present
four
clinic
trial
go
involv
raav
serotyp
design
express
factor
ix
haemophilia
common
sever
inherit
bleed
disord
caus
mutat
factor
viii
gene
significantli
problemat
treatment
larger
size
cdna
prevent
achiev
adequ
level
transgen
express
elicit
antifactor
viii
immun
respons
high
et
al
c
retin
degener
recombin
aav
use
treat
number
anim
model
limit
carri
capac
slow
onset
express
limit
abil
transduc
retin
cell
type
vitreou
nextgener
aav
produc
address
issu
creation
selfcomplementari
aav
vector
faster
onset
express
specif
mutat
selfexpos
residu
increas
transduct
vector
improv
broader
applic
advantag
characterist
direct
evolut
iter
process
select
day
et
al
agerel
macular
degener
amd
lead
central
vision
loss
elderli
individu
due
choroid
neovascular
mark
prolifer
blood
vessel
retin
pigment
epitheli
rpe
cell
lead
photoreceptor
death
fibrou
disciform
scar
format
treatment
amd
patient
requir
neutral
vascular
endotheli
growth
factor
vegf
express
modifi
solubl
receptor
design
express
vector
present
studi
phase
trial
maclachlan
et
al
leber
congenit
amaurosi
lca
autosom
recess
blind
diseas
occur
due
mutat
gene
subretin
administr
report
safe
effici
least
year
inject
current
six
clinic
trial
either
stage
go
treat
retin
diseas
simonelli
et
al
neurolog
diseas
raav
use
effect
gene
deliveri
system
treatment
central
peripher
nervou
system
almost
advers
effect
mani
clinic
trial
first
time
clinic
use
human
brain
use
treat
canavan
diseas
childhood
leukodystrophi
also
known
van
bogaertbertrand
diseas
caus
defici
enzym
aspartoacylas
asap
involv
neurosurg
administr
approxim
billion
infecti
particl
recombin
adenoassoci
viru
aav
contain
aspartoacylas
gene
aspa
directli
affect
region
brain
janson
et
al
treat
alzheim
diseas
transfer
gene
encod
nerv
growth
factor
ngf
essenti
healthier
nerv
cell
transduc
adenoassoci
nerv
growth
factor
bakay
et
al
transduct
glutam
acid
decarboxylas
gad
trophic
factor
neurturin
assess
success
differ
phase
clinic
trial
treatment
parkinson
diseas
mark
et
al
kaplitt
et
al
e
duchenn
muscular
dystrophi
dmd
dmd
sever
recess
xlink
muscl
disord
caus
mutat
gene
encod
dystrophin
gene
therapi
treat
dmd
challeng
due
larg
size
dmd
gene
howev
altern
gene
deliveri
strategi
like
exon
skip
transsplic
microand
minidystrophin
phase
iiiii
clinic
trial
found
promis
jarmin
et
al
number
phase
iiiiii
clinic
trial
underway
treatment
numer
diseas
acut
intermitt
porphyria
alpha
defici
aromat
amino
acid
decarboxylas
defici
becker
muscular
dystrophi
choroideremia
chronic
heart
failur
gastric
cancer
hiv
inflammatori
arthriti
late
infantil
neuron
ceroid
lipofuscinosi
leber
hereditari
optic
neuropathi
limb
girdl
muscular
dystrophi
macular
degener
pomp
diseas
spinal
muscular
atrophi
etc
felberbaum
futur
prospect
baculoviru
gene
deliveri
applic
stem
cell
transduct
cancer
gene
therapi
cartilag
bone
tissu
engin
also
quit
optimist
great
interest
regen
medicin
begin
advanc
identif
isol
deriv
human
stem
cell
specif
gener
humaninduc
pluripot
stem
cell
prolong
express
transgen
demonstr
multipl
multipot
stem
cell
mesenchym
neural
umbil
cord
bone
marrow
adipos
tissu
human
embryon
stem
cell
hesc
pluripot
stem
cell
baculovirus
also
custom
stabl
gene
express
stem
cell
genom
integr
downstream
therapeut
applic
exampl
deriv
unlimit
number
genet
correct
function
adult
cell
cell
replac
therapi
kotin
et
al
dedifferenti
chondrocyt
transduc
baculoviru
vector
baccb
express
bone
morphogenet
result
sustain
express
passag
chondrocyt
vitro
improv
coexpress
transform
growth
factor
beta
baculoviru
vector
chen
et
al
chondrocyt
use
grow
cartilagelik
tissu
rotat
shaft
bioreactor
demonstr
potenti
baculoviru
cartilag
tissu
engin
clinic
util
human
yet
prove
baccbbas
transduct
human
bone
marrowderiv
mesenchym
stem
cell
bmsc
also
demonstr
direct
ontogeni
bmsc
implant
transduc
cell
induc
ectop
bone
format
nude
mice
promot
calvari
bone
repair
immunocompet
rat
chuang
et
al
massiv
repair
bone
sustain
express
gene
promot
osteogenesi
angiogenesi
vegf
adiposederiv
stem
cell
asc
perform
dual
baculoviru
vector
system
transplant
asc
nzw
rabbit
result
acceler
heal
improv
bone
qualiti
angiogenesi
techniqu
also
test
rabbit
result
altogeth
support
viabil
baculovirus
stem
cell
engin
bone
format
luo
et
al
propens
baculovirus
effect
highlevel
transgen
express
exploit
cancer
gene
therapi
baculoviru
vector
tailor
suicid
tumour
suppressor
proapoptot
immunepotenti
antiangiogenesi
gene
studi
anim
tumour
model
vivo
condit
mani
anticanc
strategi
luo
et
al
wang
balasundaram
recent
stem
cell
transduc
suicid
gene
prove
benefici
curb
primari
solid
metastat
tumour
zhao
et
al
today
baculoviru
technolog
matur
level
use
plethora
applic
studi
conduct
model
organ
context
therapeut
applic
encourag
support
develop
baculovirus
preclin
applic
clinic
trial
human
diseas
treatment
deeper
holist
understand
antigen
target
cell
transduct
molecular
mechan
help
enhanc
clinic
util
uniqu
power
gene
deliveri
system
